Drugdocs | Ninlaro

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Ninlaro

Chemical Name	ixazomib
Dosage Form	Capsule (oral; 2.3 mg, 3 mg, 4 mg)
Drug Class	Inhibitors
System	Blood
Company	Millennium Pharms
Approval Year	2015

Indication

In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Ninlaro (ixazomib) Prescribing Information	2020	Takeda Pharmaceutical Company Limited, Cambridge, MA

Document Title	Year	Source
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma.	2018	NICE
Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM).	2016	Ludwig Boltzmann Institut

Document Title	Year	Source
A comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis.	2018	Clinical Lymphoma, Myeloma & Leukemia

Document Title	Year	Source
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.	2017	Expert Review of Hematology